Welcome to our dedicated page for Adia Nutrition news (Ticker: ADIA), a resource for investors and traders seeking the latest updates and insights on Adia Nutrition stock.
Adia Nutrition Inc. (OTCQB: ADIA) generates frequent news and updates centered on its work in regenerative medicine, stem cell therapies, and wellness-focused healthcare. Company announcements highlight developments across its Adia Med clinical platform, Adia Labs regenerative product division, and related health and wellness investments.
Recent news has focused on Adia Med of Winter Park’s Autism Spectrum Disorder (ASD) clinical study, a randomized interventional trial listed on ClinicalTrials.gov (NCT07304440). Releases describe IRB approval from BeyondBound, the study’s design comparing glutathione alone to glutathione combined with AdiaVita, and the launch of patient recruitment for approximately 100 children ages 3–12. These updates provide insight into Adia’s clinical research pipeline and its approach to combining antioxidants with umbilical cord blood-derived stem cells and exosomes.
News items also cover corporate and capital markets milestones, such as Adia’s uplisting to the OTCQB Venture Market, completion of SEC Rule 15c2‑11 requirements, and the filing of a Form 10 registration statement as a step toward full reporting status. Operational highlights include revenue growth commentary, expansion of the company’s sales infrastructure, partnerships that extend clinic oversight and marketing capabilities, and initiatives to broaden access to Adia Labs products and Adia Med services.
Additional coverage features partnerships and leadership appointments, including collaborations with media and marketing organizations and the addition of senior executives to support revenue generation and clinic network expansion. Visitors to this ADIA news page can review these releases to follow Adia Nutrition’s clinical studies, regenerative therapy offerings, clinic partnerships, and regulatory progress over time.
Adia Nutrition (OTCQB: ADIA) has been selected as a preferred vendor for the PI Doctors Elite Community, gaining access to a network of over 4,000 personal injury physicians across the United States. This strategic partnership positions Adia Labs to tap into the $50 billion personal injury care market.
Through this partnership, Adia Labs will provide its regenerative products, including AdiaVita and AdiaLink, to physicians treating injury-related conditions. A key advantage is that these therapies may be covered by auto insurance when prescribed, bypassing traditional health insurance requirements.
The partnership follows Adia's recent expansion into the $25 billion wound care market and complements their national television campaign promoting regenerative solutions.
Adia Nutrition Inc. (OTCQB: ADIA) has announced a strategic partnership between its clinical division, Adia Med, and Venture Medical to enter the $25 billion U.S. wound care market. The collaboration provides Adia Med with HCPCS billable products optimized for insurance reimbursement, targeting conditions like diabetic ulcers, venous ulcers, and pressure sores.
The partnership builds on Adia Med's existing approvals with UnitedHealthcare and Aetna, with active filings for TRICARE. Venture Medical will provide patient review and preliminary insurance verification services to streamline the reimbursement process. This expansion aligns with Adia Med's strategy to create a high-margin revenue stream while expanding access to advanced wound care solutions.
Adia Nutrition (OTCQB: ADIA) has launched its second national television campaign highlighting Adia Med's regenerative stem cell treatments at its Winter Park, Florida clinic. The campaign emphasizes U.S.-based therapies for conditions including sports injuries, orthopedic care, chronic pain, and wound repair.
The company is targeting the $25 billion wound care market and aims to make regenerative therapies more accessible domestically. Adia Med is currently in-network with UnitedHealthcare and Aetna, with pending TRICARE approval. The initiative is supported by favorable legislation like Florida's SB1768, which recognizes stem cell therapy benefits.
Adia Nutrition Inc. (OTCQB: ADIA) has announced its clinical division, Adia Med's expansion into the advanced wound care market, valued at $25.84 billion in 2025. The market is projected to reach $38.39 billion by 2034, driven by growing demand from 8.2 million Americans requiring chronic wound treatment annually.
The company will initially offer wound care services at its Winter Park, Florida clinic, with plans for expansion. Adia Med is already in-network with major insurers including UnitedHealthcare and Aetna, facilitating immediate patient access. The expansion targets high-reimbursement opportunities while addressing critical healthcare needs, particularly for diabetic foot ulcers, pressure sores, and post-surgical wounds.
Adia Nutrition Inc. (OTCQB: ADIA) has announced that its healthcare clinic, Adia Med, has received approval as a UnitedHealthcare provider, effective August 1, 2025. This strategic development positions Adia Med within the $5.3 trillion U.S. healthcare market, enabling access to its regenerative medicine treatments for UnitedHealthcare members.
Located in Winter Park, Florida, Adia Med specializes in minimally invasive therapies for orthopedic injuries, chronic pain, and wound repair. The clinic is staffed by physicians and Advanced Practice Registered Nurses (APRNs), offering personalized care using regenerative medicine treatments. The company is also seeking strategic partnerships and offering licensing opportunities for clinic owners interested in integrating Adia's regenerative therapies.
Adia Nutrition (OTCQB: ADIA) has announced its entry into the $3.9 billion glutathione market through two key initiatives. The company's subsidiary, Adia Med, is incorporating glutathione IV therapies into its treatment protocols at select clinics, complementing its existing stem cell and exosome treatments. Additionally, Adia Labs has launched Glutaryl Transdermal Glutathione Spray, utilizing sub-nanotechnology for enhanced skin absorption.
The company's expansion includes integrating glutathione with its Adia Vita treatment (featuring 100 million stem cells and 3 trillion exosomes) for various conditions including orthopedics, pain management, and wound repair. The new transdermal spray product is positioned as a high-margin offering targeting athletes, wellness enthusiasts, and individuals seeking non-invasive options.
Adia Nutrition Inc. (OTCQB: ADIA) has achieved a significant milestone with its medical subsidiary, Adia Med, securing approval as an in-network provider for Aetna health insurance effective July 25, 2025. The partnership grants access to 39 million Aetna members and a network of 1.8 million health professionals.
The company is also on track for approval with United Healthcare, the nation's largest health insurer with 15% market share, expected by August 1, 2025. These partnerships will enable broader access to Adia Med's regenerative therapies, including Autologous Hematopoietic Stem Cell Transplantation (AHSCT), Therapeutic Plasma Exchange (TPE), and Medical Nutrition Therapy (MNT).
Adia Nutrition Inc. (OTCQB: ADIA) has announced that its medical subsidiary, Adia Med, has filed to become an in-network provider with TRICARE, a healthcare program serving 9.5 million military-related beneficiaries. The company expects to secure TRICARE provider status by August 31, 2025, accessing a program that disbursed $50.6 billion in medical treatments in FY2019.
Additionally, Adia Med anticipates approval as a United Healthcare provider by August 1, 2025, and has begun submitting its first patient insurance claims. The company offers regenerative treatments including Umbilical Cord Blood Stem Cell therapies, Autologous Hematopoietic Stem Cell Transplantation, and Therapeutic Plasma Exchange at its Winter Park clinic.
Adia Nutrition (OTCQB: ADIA) has partnered with CareCredit to offer patients financing options of up to $25,000 for medical treatments. This strategic move taps into the $48.35 billion U.S. healthcare finance solutions market as of 2023.
The company has transitioned from its previous provider, Cherry, to CareCredit as its primary financing partner. This partnership aims to make Adia's advanced treatments, including stem cell treatments and regenerative protocols, more accessible to patients through flexible payment options.
Adia Nutrition Inc. (OTCQB: ADIA) has announced the grand opening of its first licensed clinic, Adia Med of San Antonio, located in Texas. The clinic, led by Dr. Michele DeLeon, will offer FDA-registered regenerative medicine products including AdiaVita (containing 100 million viable cells and 3 trillion exosomes per unit) and AdiaLink (3.5 trillion exosomes per unit).
The new facility will collaborate with Adia Med of Winter Park on a clinical study investigating regenerative therapies for autism. The company is actively expanding its network through licensing opportunities, marking this opening as a strategic milestone in its growth plan.